Physician profile
Daniel R Fields
NPI 1639197098
$1,344.84
in general payments reported to CMS, 2019-2025
11 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.23 · 2021: $55.68 · 2022: $152 · 2023: $320 · 2024: $397 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $511.35 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $224.83 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $162.89 | 2021-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $118.83 | 2022-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $107.38 | 2023-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $78.27 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $48.84 | 2022-2023 | |
| Abbvie INC. | $32.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.53 | 2022 | |
| Ibsa Pharma INC. | $17.60 | 2024 | Licart, Tirosint |
| Nalpropion Pharmaceuticals LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.